A Randomized, Open-label, Phase 2 Trial of Sipuleucel-T With Concurrent Versus Sequential Administration of Abiraterone Acetate Plus Prednisone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC).
Phase of Trial: Phase II
Latest Information Update: 14 Jun 2017
At a glance
- Drugs Sipuleucel-T (Primary) ; Abiraterone acetate; Prednisone
- Indications Prostate cancer
- Focus Pharmacodynamics
- Acronyms STAMP
- Sponsors Dendreon Corporation
- 10 Jun 2017 Biomarkers information updated
- 06 Jun 2017 Results from NCT01431391, NCT01981122 and NCT01487863 studies presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
- 03 Jun 2017 According to a Dendreon corporation media release, the results from this and other two (STRIDE and STAND) studies will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History